The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Combining immunotherapy and targeted therapies in cancer treatment
Open accessAbstract
During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer chemotherapies were initially identified through screens for compounds that killed rapidly dividing cells. These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities and frequently acquired resistance. More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy. Targeted approaches aim to inhibit molecular pathways that are crucial for tumour growth and maintenance; whereas, immunotherapy endeavours to stimulate a host immune response that effectuates long-lived tumour destruction. Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Self-citationO'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W., & Young, H. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3596 · Cited by 739
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Self-citationDougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Self-citationThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420
Leffers, N., Gooden, M. J. M., de Jong, R. A., Hoogeboom, B.-N., ten Hoor, K. A., Hollema, H., Boezen, H. M., van der Zee, A. G. J., Daemen, T., & Nijman, H. W. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0583-5 · Cited by 402
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Boruchov, A. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24772 · Cited by 377
Danna, E. A., Sinha, P., Gilbert, M., Clements, V. K., Pulaski, B. A., & Ostrand-Rosenberg, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2646 · Cited by 371
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
An Oscillatory Switch in mTOR Kinase Activity Sets Regulatory T Cell Responsiveness
Procaccini, C., De Rosa, V., Galgani, M., Abanni, L., Calì, G., Porcellini, A., Carbone, F., Fontana, S., Horvath, T. L., La Cava, A., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.11.024 · Cited by 368
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
Richardson, P. G., Mitsiades, C., Hideshima, T., & Anderson, K. C. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.042905.122625 · Cited by 361
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Disis, M. L., Wallace, D. R., Gooley, T. A., Dang, Y., Slota, M., Lu, H., Coveler, A. L., Childs, J. S., Higgins, D. M., Fintak, P. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6789 · Cited by 300
Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., & Brossart, P. (2008) · Blood · doi:10.1182/blood-2007-02-075945 · Cited by 288
Quoix, E., Ramlau, R., Westeel, V., Papai, Z., Madroszyk, A., Riviere, A., Koralewski, P., Breton, J.-L., Stoelben, E., Braun, D., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70259-5 · Cited by 269
Skov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259
Görgün, G., Calabrese, E., Soydan, E., Hideshima, T., Perrone, G., Bandi, M., Cirstea, D., Santo, L., Hu, Y., Tai, Y.-T., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279893 · Cited by 230
Alfaro, C., Suarez, N., Gonzalez, A., Solano, S., Erro, L., Dubrot, J., Palazon, A., Hervas-Stubbs, S., Gurpide, A., Lopez-Picazo, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604965 · Cited by 214
Haber, D. A., Gray, N. S., & Baselga, J. (2011) · Cell · doi:10.1016/j.cell.2011.03.026 · Cited by 214
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202
Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling
Nefedova, Y., Cheng, P., Gilkes, D., Blaskovich, M., Beg, A. A., Sebti, S. M., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4338 · Cited by 196
Li, B., VanRoey, M., Wang, C., Chen, T.-H. T., Korman, A., & Jooss, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1825 · Cited by 191
The DNA Damage Response Arouses the Immune System
Gasser, S., & Raulet, D. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4603 · Cited by 178
Kocak, E., Lute, K., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2128 · Cited by 177
Shi, J., Tricot, G. J., Garg, T. K., Malaviarachchi, P. A., Szmania, S. M., Kellum, R. E., Storrie, B., Mulder, A., Shaughnessy, J. D., Barlogie, B., et al. (2008) · Blood · doi:10.1182/blood-2007-03-078535 · Cited by 175
Zhang, B., Kracker, S., Yasuda, T., Casola, S., Vanneman, M., Hömig-Hölzel, C., Wang, Z., Derudder, E., Li, S., Chakraborty, T., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.031 · Cited by 172
Self-citationDechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T., Schneider-Merck, T., Lammerts van Bueren, J. J., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6226 · Cited by 166
Larmonier, N., Janikashvili, N., LaCasse, C. J., Larmonier, C. B., Cantrell, J., Situ, E., Lundeen, T., Bonnotte, B., & Katsanis, E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6955 · Cited by 160
Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156
Experimental mouse tumour models: what can be learnt about human cancer immunology?
Dranoff, G. (2011) · Nature reviews. Immunology · doi:10.1038/nri3129 · Cited by 154
Self-citationInhibition of GSK‐3β activity attenuates proliferation of human colon cancer cells in rodents
Shakoori, A., Mai, W., Miyashita, K., Yasumoto, K., Takahashi, Y., Ooi, A., Kawakami, K., & Minamoto, T. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00545.x · Cited by 153
Kimura, Y., Tsukada, J., Tomoda, T., Takahashi, H., Imai, K., Kanae, S., Sunamura, M., Yonemitsu, Y., Shimodaira, S., Koido, S., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e31822398c6 · Cited by 148
IAP inhibitors enhance co-stimulation to promote tumor immunity
Dougan, M. L., Dougan, S. K., Slisz, J. K., Firestone, B., Vanneman, M. W., Draganov, D., Goyal, G., Li, W., Neuberg, D. S., Blumberg, R. S., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101123 · Cited by 147
Self-citationSTAT3: A Target to Enhance Antitumor Immune Response
Lee, H., Pal, S. K., Reckamp, K. L., Figlin, R. A., & Yu, H. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_51 · Cited by 146
Bose, A., Taylor, J. L., Alber, S. M., Watkins, S. C., García, J. A., Rini, B. I., Ko, J. S., Cohen, P. A., Finke, J. H., & Storkus, W. J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25863 · Cited by 145
(Un)expected roles of c-IAPs in apoptotic and NFκB signaling pathways
Varfolomeev, E. E., & Vucic, D. (2008) · Cell Cycle · doi:10.4161/cc.7.11.5959 · Cited by 144
Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition
Hallett, W. H. D., Ames, E., Motarjemi, M., Barão, I., Shanker, A., Tamang, D., Sayers, T. J., Hudig, D., & Murphy, W. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.163 · Cited by 139
Miller, R. E., Jones, J., Le, T., Whitmore, J. B., Boiani, N., Gliniak, B., & Lynch, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.1792 · Cited by 138
Araki, K., Ellebedy, A. H., & Ahmed, R. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.08.006 · Cited by 137
Immunotherapy: Bewitched, Bothered, and Bewildered No More
Steinman, R. M., & Mellman, I. (2004) · Science · doi:10.1126/science.1099688 · Cited by 136
Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3243 · Cited by 135
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., d’Escamard, V., Forni, G., & Inghirami, G. (2008) · Nature Medicine · doi:10.1038/nm1769 · Cited by 129
Farsaci, B., Higgins, J. P., & Hodge, J. W. (2011) · International Journal of Cancer · doi:10.1002/ijc.26219 · Cited by 127
Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K. L., Scuto, A., Jensen, M. C., Deng, J., Forman, S. J., Figlin, R. A., & Yu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1293 · Cited by 125
May, K. F., Chen, L., Zheng, P., & Liu, Y. (2002) · PubMed · Cited by 122
Mai, W., Kawakami, K., Shakoori, A., Kyo, S., Miyashita, K., Yokoi, K., Jin, M., Shimasaki, T., Motoo, Y., & Minamoto, T. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0973 · Cited by 119
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
Wang, Y., Wang, X.-Y., Subjeck, J. R., Shrikant, P., & Kim, H. L. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.15 · Cited by 114
Bekaii‐Saab, T., Roda, J. M., Guenterberg, K. D., Ramaswamy, B., Young, D. C., Ferketich, A. K., Lamb, T., Grever, M. R., Shapiro, C. L., & Carson, W. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0820 · Cited by 113
Poggi, A. D., Catellani, S., Garuti, A., Pierri, I., Gobbi, M., & Zocchi, M. R. (2009) · Leukemia · doi:10.1038/leu.2008.354 · Cited by 109
Wolpoe, M. E., Lutz, E. R., Ercolini, A. M., Murata, S., Ivie, S. E., Garrett, E. S., Emens, L. A., Jaffee, E. M., & Reilly, R. T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.2161 · Cited by 104
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
Jaime-Ramirez, A. C., Mundy-Bosse, B. L., Kondadasula, S., Jones, N. B., Roda, J. M., Mani, A., Parihar, R., Karpa, V., Papenfuss, T. L., LaPerle, K. M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000328 · Cited by 100
Yun, T. J., Harning, E. K., Giza, K., Rabah, D., Li, P., Arndt, J. W., Luchetti, D., Biamonte, M. A., Shi, J., Lundgren, K., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000222 · Cited by 99
Activation of Akt as a Mechanism for Tumor Immune Evasion
Noh, K. H., Kang, T. H., Kim, J. H., Pai, S. I., Lin, K. Y., Hung, C., Wu, T. ‐., & Kim, T. W. (2008) · Molecular Therapy · doi:10.1038/mt.2008.255 · Cited by 98
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 97
Fionda, C., Soriani, A., Malgarini, G., Iannitto, M. L., Santoni, A., & Cippitelli, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901797 · Cited by 93
IFN-β Production by TLR4-Stimulated Innate Immune Cells Is Negatively Regulated by GSK3-β
Wang, H., Garcia, C. A. S., Rehani, K., Cekic, C., Alard, P., Kinane, D. F., Mitchell, T. C., & Martin, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6797 · Cited by 87
Rossi, L. E., Avila, D. E., Spallanzani, R. G., Ziblat, A., Fuertes, M. B., Lapyckyj, L., Croci, D. O., Rabinovich, G. A., Domaica, C. I., & Zwirner, N. W. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0711339 · Cited by 84
Hsu, Y.-F., Ajona, D., Corrales, L. P., López-Picazo, J. M., Gúrpide, A., Montuenga, L. M., & Pı́o, R. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-139 · Cited by 84
Maréchal, R., Schutter, J. D., Nagy, N., Demetter, P., Lemmers, A., Deviere, J. M. E., Salmon, I. J., Tejpar, S., & Laethem, J. V. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-340 · Cited by 82
Jiang, Q., Weiss, J. M., Back, T. C., Chan, T., Ortaldo, J. R., Guichard, S. M., & Wiltrout, R. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3968 · Cited by 82
Kamrava, M. R., Bernstein, M. B., Camphausen, K. A., & Hodge, J. W. (2009) · Molecular BioSystems · doi:10.1039/b911313b · Cited by 78
Kim, P. S., Armstrong, T. D., Hong, S., Wolpoe, M. E., Weiss, V. L., Manning, E. A., Huang, L., Murata, S., Sgouros, G., Emens, L. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34333 · Cited by 78
Correale, P., Botta, C., Cusi, M. G., Vecchio, M. T. D., Santi, M. M. D., Savellini, G. G., Bestoso, E., Apollinari, S., Mannucci, S., Marra, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26181 · Cited by 77
Ladoire, S., Arnould, L., Mignot, G., Apétoh, L., Rébé, C., Martin, F., Fumoleau, P., Coudert, B. P., & Ghiringhelli, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.261 · Cited by 74
Targeting AKT Signaling Sensitizes Cancer to Cellular Immunotherapy
Hähnel, P. S., Thaler, S., Antunes, E., Huber, C., Theobald, M., & Schüler, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6286 · Cited by 73
Chanan-Khan, A. A., Chitta, K. S., Ersing, N., Paulus, A., Masood, A., Sher, T., Swaika, A., Wallace, P. K., Mashtare, T. L., Wilding, G. E., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08882.x · Cited by 71
Yang, D., Park, J., Jin, C.-J., Kang, H., Nam, J., Rhee, J.-H., Kim, Y., Chung, S.-Y., Choi, S.-J.-N., Kim, H., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.09.006 · Cited by 66
Böll, B., Eltaib, F. I., Reiners, K. S., von Tresckow, B., Tawadros, S., Simhadri, V. R., Burrows, F. J., Lundgren, K., Hansen, H. P., Engert, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0213 · Cited by 62
The Proteasome Inhibitor Bortezomib Sensitizes Melanoma Cells toward Adoptive CTL Attack
Seeger, J. M., Schmidt, P., Brinkmann, K., Hombach, A. A., Coutelle, O., Zigrino, P., Wagner‐Stippich, D., Mauch, C., Abken, H., Krönke, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3175 · Cited by 61
Wang, Y., Camirand, G., Lin, Y., Froicu, M., Deng, S., Shlomchik, W. D., Lakkis, F. G., & Rothstein, D. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903805 · Cited by 61
Kilinc, M. O., Gu, T., Harden, J. L., Virtuoso, L. P., & Egilmez, N. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802793 · Cited by 57
Jain, N., Reuben, J. M., Kantarjian, H. M., Li, C., Gao, H., Lee, B.-N., Cohen, E. N., Ebarb, T., Scheinberg, D. A., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24468 · Cited by 54
Avella, D. M., Li, G., Schell, T. D., Liu, D., Zhang, S. S.-M., Lou, X., Berg, A. S., Kimchi, E. T., Tagaram, H. R. S., Yang, Q. X., et al. (2011) · Hepatology · doi:10.1002/hep.24652 · Cited by 48
Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell
Bae, J. E., Mitsiades, C. S., Tai, Y., Bertheau, R. C., Shammas, M. A., Batchu, R. B., Li, C., Catley, L., PRABHALA, R. H., Anderson, K. C., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7730 · Cited by 45
Feng, X., Yan, J., Wang, Y., Zierath, J. R., Nordenskjöld, M., Henter, J., Fadeel, B., & Zheng, C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.003 · Cited by 43
Kawabe, M., Mandić, M., Taylor, J. L., Vasquez, C. A., Wesa, A. K., Neckers, L. Μ., & Storkus, W. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4511 · Cited by 39
Wang, X., Ottosson, A., Ji, C., Feng, X., Nordenskjöld, M., Henter, J., Fadeel, B., & Zheng, C. (2009) · Haematologica · doi:10.3324/haematol.13783 · Cited by 36
Lanuti, P., Bertagnolo, V., Pierdomenico, L., Bascelli, A., Santavenere, E., Alinari, L., Capitani, S., Miscia, S., & Marchisio, M. (2009) · Cell Research · doi:10.1038/cr.2009.80 · Cited by 32
Catellani, S., Pierri, I., Gobbi, M., Poggi, A. D., & Zocchi, M. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018925 · Cited by 25
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Metadata
- Authors
- Vanneman, M., & Dranoff, G.
- Venue
- Nature Reviews Cancer
- Published
- 2012-03-22
- Volume
- 12
- Issue
- 4
- Pages
- 237-251
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2052874737
- Cited by
- 1,586
- References
- 126
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.